Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.73 |
| ▸ | KDR | P35968 | 10/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837024 | 0.87 | EGFR (0.68) | EGFRKDRPDGFRBPDGFRATSHR | |
| SCHEMBL17837013 | 0.78 | EGFR (0.70) | EGFRKDRPDGFRBPDGFRA | |
| SCHEMBL2256504 | 0.76 | ABCG2 (0.73) | ABCG2ABCB1ABCC1 | |
| SCHEMBL13276260 | 0.76 | EGFR (0.71) | EGFRKDRPDGFRBPDGFRA | |
| SCHEMBL17837009 | 0.76 | EGFR (0.63) | EGFRKDRPDGFRBPDGFRATSHR | |
| SCHEMBL17837021 | 0.76 | KDR (0.75) | EGFRKDRPDGFRBPDGFRA | |
| SCHEMBL17837007 | 0.76 | KDR (0.63) | EGFRKDRPDGFRBPDGFRATSHR | |
| SCHEMBL17837023 | 0.76 | EGFR (0.59) | EGFRKDRPDGFRBPDGFRATSHR | |
| SCHEMBL17837027 | 0.74 | KDR (0.72) | EGFRKDRPDGFRBPDGFRA | |
| SCHEMBL17837022 | 0.72 | KDR (1.00) | EGFRKDRPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-12-28 | — | — | US | disclosed |
| US-9777012-B2 | Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2016100495-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | ERBB2, MAP2, TUBB6 | EGFR 8/4885KDR 167/4885PDGFRB 232/4885 |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | ERBB2, DCK, DHFR | EGFR 38/4885KDR 402/4885PDGFRB 394/4885 |
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | ERBB2, DCK, DHFR | EGFR 38/4885KDR 402/4885PDGFRB 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.